tiprankstipranks
Eyepoint Pharma (EYPT)
NASDAQ:EYPT
US Market
EYPT
EyePoint Pharmaceuticals
RESEARCH TOOLSreports
Want to see EYPT full AI Analyst Report?

EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

1,004 Followers
See the Price Targets and Ratings of:

EYPT Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
EyePoint
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EYPT Stock 12 Month Forecast

Average Price Target

$36.78
▲(146.33% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for EyePoint Pharmaceuticals in the last 3 months. The average price target is $36.78 with a high forecast of $68.00 and a low forecast of $20.00. The average price target represents a 146.33% change from the last price of $14.93.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","69":"$69","21.75":"$21.8","37.5":"$37.5","53.25":"$53.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.77777777777778,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,21.75,37.5,53.25,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.15,17.369230769230768,21.588461538461537,25.807692307692307,30.026923076923076,34.246153846153845,38.465384615384615,42.684615384615384,46.90384615384615,51.12307692307692,55.34230769230769,59.56153846153846,63.78076923076923,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.15,14.967521367521368,16.785042735042737,18.602564102564102,20.42008547008547,22.23760683760684,24.055128205128206,25.872649572649575,27.690170940170944,29.50769230769231,31.325213675213675,33.14273504273505,34.96025641025641,{"y":36.77777777777778,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.15,13.676923076923078,14.203846153846154,14.730769230769232,15.257692307692308,15.784615384615385,16.31153846153846,16.838461538461537,17.365384615384617,17.892307692307693,18.41923076923077,18.946153846153848,19.473076923076924,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.42,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.73,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.915,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.27,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.29,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.34,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.02,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.34,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.15,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$68.00Average Price Target$36.78Lowest Price Target$20.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on EYPT
Debanjana Chatterjee
JonesTrading
JonesTrading
$43
Buy
188.01%
Upside
Reiterated
06/05/26
Wet AMD KOL Event with Dr. 10am ET What’s new? We are rescheduling our wet AMD KOL event with Dr. Ferhina Ali (originally planned for a virtual call on 10am ET.
Mizuho Securities Analyst forecast on EYPT
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$36
Buy
141.13%
Upside
Reiterated
06/05/26
Analysts' Top Healthcare Picks: Liquidia Technologies (LQDA), Healthequity (HQY)
RBC Capital Analyst forecast on EYPT
Lisa Walter
RBC Capital
RBC Capital
$39→$37
Buy
147.82%
Upside
Reiterated
05/07/26
RBC Capital Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)
H.C. Wainwright Analyst forecast on EYPT
Yi Chen
H.C. Wainwright
H.C. Wainwright
$30
Buy
100.94%
Upside
Reiterated
05/07/26
Yi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress
Guggenheim Analyst forecast on EYPT
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$68
Buy
355.46%
Upside
Reiterated
05/06/26
EyePoint Pharmaceuticals (EYPT) Gets a Buy from Guggenheim
TD Cowen Analyst forecast on EYPT
Tara Bancroft
TD Cowen
TD Cowen
$20
Buy
33.96%
Upside
Reiterated
05/06/26
Analysts Are Bullish on These Healthcare Stocks: EyePoint Pharmaceuticals (EYPT), BeOne Medicines (ONC)
Chardan Capital Analyst forecast on EYPT
Daniil Gataulin
Chardan Capital
Chardan Capital
$29
Buy
94.24%
Upside
Reiterated
05/06/26
Analysts Are Bullish on Top Healthcare Stocks: Trevi Therapeutics (TRVI), EyePoint Pharmaceuticals (EYPT)
J.P. Morgan Analyst forecast on EYPT
Tessa Romero
J.P. Morgan
J.P. Morgan
$33
Buy
121.03%
Upside
Reiterated
03/10/26
J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
Citi Analyst forecast on EYPT
Yigal Nochomovitz
Citi
Citi
$31→$35
Buy
134.43%
Upside
Reiterated
03/09/26
EyePoint price target raised to $35 from $31 at CitiEyePoint price target raised to $35 from $31 at Citi
Jefferies Analyst forecast on EYPT
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$33
Buy
121.03%
Upside
Reiterated
03/05/26
EyePoint Pharmaceuticals (EYPT) Receives a Buy from Jefferies
Scotiabank Analyst forecast on EYPT
Greg Harrison
Scotiabank
Scotiabank
$18
Buy
20.56%
Upside
Reiterated
08/07/25
Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on EYPT
Debanjana Chatterjee
JonesTrading
JonesTrading
$43
Buy
188.01%
Upside
Reiterated
06/05/26
Wet AMD KOL Event with Dr. 10am ET What’s new? We are rescheduling our wet AMD KOL event with Dr. Ferhina Ali (originally planned for a virtual call on 10am ET.
Mizuho Securities Analyst forecast on EYPT
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$36
Buy
141.13%
Upside
Reiterated
06/05/26
Analysts' Top Healthcare Picks: Liquidia Technologies (LQDA), Healthequity (HQY)
RBC Capital Analyst forecast on EYPT
Lisa Walter
RBC Capital
RBC Capital
$39→$37
Buy
147.82%
Upside
Reiterated
05/07/26
RBC Capital Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)
H.C. Wainwright Analyst forecast on EYPT
Yi Chen
H.C. Wainwright
H.C. Wainwright
$30
Buy
100.94%
Upside
Reiterated
05/07/26
Yi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress
Guggenheim Analyst forecast on EYPT
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$68
Buy
355.46%
Upside
Reiterated
05/06/26
EyePoint Pharmaceuticals (EYPT) Gets a Buy from Guggenheim
TD Cowen Analyst forecast on EYPT
Tara Bancroft
TD Cowen
TD Cowen
$20
Buy
33.96%
Upside
Reiterated
05/06/26
Analysts Are Bullish on These Healthcare Stocks: EyePoint Pharmaceuticals (EYPT), BeOne Medicines (ONC)
Chardan Capital Analyst forecast on EYPT
Daniil Gataulin
Chardan Capital
Chardan Capital
$29
Buy
94.24%
Upside
Reiterated
05/06/26
Analysts Are Bullish on Top Healthcare Stocks: Trevi Therapeutics (TRVI), EyePoint Pharmaceuticals (EYPT)
J.P. Morgan Analyst forecast on EYPT
Tessa Romero
J.P. Morgan
J.P. Morgan
$33
Buy
121.03%
Upside
Reiterated
03/10/26
J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
Citi Analyst forecast on EYPT
Yigal Nochomovitz
Citi
Citi
$31→$35
Buy
134.43%
Upside
Reiterated
03/09/26
EyePoint price target raised to $35 from $31 at CitiEyePoint price target raised to $35 from $31 at Citi
Jefferies Analyst forecast on EYPT
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$33
Buy
121.03%
Upside
Reiterated
03/05/26
EyePoint Pharmaceuticals (EYPT) Receives a Buy from Jefferies
Scotiabank Analyst forecast on EYPT
Greg Harrison
Scotiabank
Scotiabank
$18
Buy
20.56%
Upside
Reiterated
08/07/25
Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering EyePoint Pharmaceuticals

3 Months
Graig SuvannavejhMizuho Securities
Success Rate
12/22 ratings generated profit
55%
Average Return
+12.59%
Copying Graig Suvannavejh's trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +12.59% per trade.
1 Year
Debanjana ChatterjeeJonesTrading
Success Rate
9/15 ratings generated profit
60%
Average Return
+32.31%
Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +32.31% per trade.
2 Years
Debanjana ChatterjeeJonesTrading
Success Rate
10/15 ratings generated profit
67%
Average Return
+20.79%
Copying Debanjana Chatterjee's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +20.79% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EYPT Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
13
19
16
17
8
Buy
1
2
1
2
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
21
17
19
9
In the current month, EYPT has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. EYPT average Analyst price target in the past 3 months is 36.78.
Each month's total comprises the sum of three months' worth of ratings.

EYPT Financial Forecast

EYPT Earnings Forecast

Next quarter’s earnings estimate for EYPT is -$0.94 with a range of -$1.20 to -$0.77. The previous quarter’s EPS was -$0.99. EYPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year EYPT has Performed in-line its overall industry.
Next quarter’s earnings estimate for EYPT is -$0.94 with a range of -$1.20 to -$0.77. The previous quarter’s EPS was -$0.99. EYPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year EYPT has Performed in-line its overall industry.

EYPT Sales Forecast

Next quarter’s sales forecast for EYPT is $383.00K with a range of $0.00 to $700.00K. The previous quarter’s sales results were $696.00K. EYPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year EYPT has Performed in-line its overall industry.
Next quarter’s sales forecast for EYPT is $383.00K with a range of $0.00 to $700.00K. The previous quarter’s sales results were $696.00K. EYPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year EYPT has Performed in-line its overall industry.

EYPT Stock Forecast FAQ

What is EYPT’s average 12-month price target, according to analysts?
Based on analyst ratings, Eyepoint Pharma’s 12-month average price target is 36.78.
    What is EYPT’s upside potential, based on the analysts’ average price target?
    Eyepoint Pharma has 146.33% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is EYPT a Buy, Sell or Hold?
          Eyepoint Pharma has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Eyepoint Pharma’s price target?
            The average price target for Eyepoint Pharma is 36.78. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $68.00 ,the lowest forecast is $20.00. The average price target represents 146.33% Increase from the current price of $14.93.
              What do analysts say about Eyepoint Pharma?
              Eyepoint Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of EYPT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.